Three winners will present at the American College Of Perioperative Medicine “Startup Pitch” program, in front of investors and other stakeholders from the healthcare ecosystem.
* The final $ amount is dependent solely on funding decisions of the investor group
Banifatemi is an entrepreneur, investor, and innovation strategist. He is the managing partner of K5 Ventures, and currently leads the AI and Frontiers Technologies and Impact initiatives with the XPRIZE foundation. He is a co-founder the AI Commons Initiative, and curator of the AI for Good Global Summit with the ITU and UN Agencies. He has managed two venture capital funds, and supports and advises companies focused on exponential technologies and transformation of humanity and society. He holds a Master’s degree in Electrical Engineering from the University of Technology of Compiègne, a Doctorate in System Design and Cognitive Sciences from the University Paris Descartes, as well as an MBA from HEC Paris. He is a regular guest lecturer and adjunct MBA professor at UC Berkeley, Chapman University, Claremont McKenna College, UC Irvine, and HEC Paris.
Currim is Chancellor’s Professor at the University of California, Irvine and Director of the Beall Center for Innovation and Entrepreneurship. The Center’s mission is to inspire innovation and entrepreneurship for the 21st century and provide education about the process and importance of becoming an entrepreneur. He is the recipient of the American Marketing Association William O’Dell Award for "the article judged to have made the most significant five-year contribution to marketing theory, methodology, and practice". Recently, he served The Paul Merage School of Business as Associate Dean of the Undergraduate Program (2012-2014). He has consulted for companies such as Altiris, AT&T, Baxter, Dell, Elcam Medical (Israel), Inabata (U.S. and Japan), Johnson and Johnson, Los Angeles Times, Orange County Register, St. Joseph’s Hospital, Twentieth Century Fox, Warner Brothers, and smaller profit and not-for-profit organizations.
Mark Konno is the Vice President of R&D, Clinical and Medical Affairs for Critical Care and Vascular at Edwards Lifesciences. During his 38 year tenure with Edwards, Mark has worked in multiple business units including Medical Delivery Systems, Critical Care, Minimally Invasive Surgery and Heart Valves. In addition to being an R&D leader, Mark has also held roles in Strategic Marketing, Business Development, and Discovery. He is currently the Managing Director of an Edwards acquisition in the Netherlands and also managed Operations for an Edwards acquisition in Texas. Under his leadership, Critical Care is currently developing predictive analytics and decision support parameters which are the first of its kind. Mark is also leading the clinical and medical affairs group for Critical Care which is now conducting pivotal and outcome trials for these innovative cutting edge decision support algorithms.
Mourlas is Senior Director, New Ventures at Johnson & Johnson Innovation, California. In this role, he focuses on medical device innovation in support of the general surgery, orthopedics, and cardiology businesses. His charge is to identify licensing, collaboration, and investment opportunities highly aligned with Johnson & Johnson business strategies by building relationships with entrepreneurs, venture investors, and key opinion leaders. Nick’s start-up experience includes founding companies in orthopedics, cardiology, and radiation oncology. He was the CEO of Tarsus Medical - acquired by Integra LifeSciences (IART), and Acumen Medical - acquired by Medtronic (MDT). Nick served as PARC’s Director of Global Healthcare Innovation and as the Xerox Innovation Group’s Healthcare Program Manager. He holds a Ph.D. in Electrical Engineering from Stanford University where he was the John B. Simpson Biomedical Innovation Technology Fellow.
As a General Partner at Norwest Ventures Len Brandt led the fund’s investment activity throughout the 1980’s in all areas of healthcare. In the 1990’s, he co-founded Mill City Ventures providing venture capital experience without venture capital control. In 2000, he funded CNS Response, providing rEEG medication guidance reports to guide psychiatric treatment. Until 2009, he organized all the financings for that start-up including taking the company public through a reverse merger and associated PIPE in 2007. In the last two years, he has again become active in venture development making significant time commitments to young ventures in Orange County, Chennai, India and Barcelona, Spain. Included are ventures in Botox-like neurotoxins, pest repellency and in-silico platform for drug repurposing.
Fuchs is a motivated strategic management professional with over 20 years of experience impacting corporate performance by ensuring delivery of effective healthcare services and practices. His specific expertise includes insurance and managed health plan operations, health information technology, data analytics and population health, data governance and liquidity, QIO/REC operations and hospital and facility management. He has worked in a variety of health care settings, including serving as the Chief Operating Officer of Arkansas Foundation for Medical Care and as the executive responsible for HITArkansas; CEO of the University MSO, an executive in a number of HMO and PPO organizations and past Chairman, Board of Directors of SCAN Health Plan. Mr. Fuchs is a member of the Noloki Cybersecurity and Healthcare IT Advisory Board.
Dr. Gillman is an accomplished Orthopedic Surgeon who has been in private practice in Orange County for 19 years. He performed the first known outpatient total knee replacement in OC in 2011, well before this mode of practice became common in the US. He achieved his Health Care Executive MBA with Beta Gamma Sigma honors from UC Irvine in 2008. He is founder and chief medical officer of BullseyeOrtho. His custom 3D- printed surgical instruments have been demonstrated to improve accuracy by 90 percent in hip replacement surgery. Dr. Gillman is the joint replacement service line director in a novel program at 7 German Saudi hospitals in the Middle East where he oversees premiere U.S. surgeons in the program.
Henson is a medical device executive with over 35 years of experience in product development, design and manufacturing. He has co-founded multiple medical device companies including PhageTech, Inc, a development stage company that is developing novel technology for immunodiagnostics. Previously, he was co-founder and CEO of Source Scientific LLC, a medical instrument and device development firm that was ranked in 2012 as one of the Inc. 5000 fastest growing companies in the US. Source Scientific developed and manufactured products for many well-known in-vitro diagnostic, ophthalmic, surgical and medical device companies. An experienced CEO, Richard has worked with many high-tech firms in biomedical, consumer and critical power industries. He has also worked for several Fortune 500 firms including CBS and GE.
Dr. Sadri is board-certified and fellowship-trained in cataract surgery, LASIK, and glaucoma surgery. Dr. Sadri also has extensive experience and a refined technique in performing many cosmetic procedures such as upper and lower eyelid blepharoplasty. Dr. Sadri has delivered over 300 invited lectures both nationally and internationally in which he teaches other eye surgeons the latest techniques for vision correction and preservation. His clinical and research work has earned him honors and grants from the American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, National Institutes of Health, Alcon Laboratories, and Allergan. Dr. Sadri is the founder and past president of the Orange County Glaucoma Society and is an active member of the American College of Surgeons.
Shen created a diverse and successful career growing companies and leveraging business opportunities. For more than two decades, he managed and lead software projects, software creation and implementations, and ran P&L operations with sales responsibility for publicly traded software vendors. With his international background, experience and training, he guided a wide range of companies, including B2B, B2C and non-profit organizations. In addition to technology project management, Shen is expert in creating and implementing management strategy: developing and executing market penetration, defining strategies for growth and allocating resources to achieve them, and selecting and negotiating joint venture opportunities. He has operated in Fortune 1000 sectors, local and federal governments and businesses in aerospace, financial, healthcare, sales and marketing, distribution and retail.
Alex Siemons has over two decades of industry background in medical devices with a focus on innovative technologies and solutions. He currently leads the Discovery and Technology group for Edwards Lifesciences in Critical Care where his team’s mission is to create disruptive solutions for the Critical Care environment. Alex joined Edwards in 2007 and has played a leadership role in multiple product launches and innovations. Prior, Alex has worked in both large and start-up companies where he had generated significant IP. Alex holds a BS in Mechanical Engineering from the University of California Santa Barbara.
Shalabh Gupta, MD, MPA is the CEO of Globavir, Inc. a biotechnology company focused on oncology. Previously, Dr. Gupta worked at Genentech where his work focused on immunology products with regard to competitive positioning and working with brand teams to create franchise strategies. Before Genentech, Dr. Gupta worked as a stock analyst at UBS covering large cap pharmaceuticals, and while at Rodman & Renshaw, he covered small/mid cap biotechnology companies. His work also included analysis of M&A targets and strategic partnerships. Dr. Gupta also served as an advisor to an early stage venture fund based in NYC and earlier in his career, he served as medical director for early stage medical device and biotechnology companies.
Sponsoring our Hackathon is more than just putting your money where your mouth is. It is a way to become a change agent within surgical care innovation. This is a great way to earn karma points and support an amazing community of built environment and tech innovators.
Our pricing is designed to allow everyone to participate.
|Registrant Category||Early Birds
(by Sep. 15th 2018)
(after Sep. 15th 2018)
Edwards Lifesciences Corp
One Edwards Way
Irvine, CA 92614
For our out-of-town visitors here are some hotel options:
17900 Jamboree Rd
Irvine, CA 92614
Avenue of the Arts Hotel
3350 Avenue of the Arts
Costa Mesa, California 92626
4500 MacArthur Blvd
Newport Beach, CA 92660